You are here: Home / Sites / University of Michigan / Chinnaiyan, Arul M.

Chinnaiyan, Arul M. (M.D., Ph.D.)

PI, University of Michigan, 734-615-4062

Contact Information

EDRN Principal Investigator

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Characterization of SPINK1 in Prostate Cancer (A sub-study of a single biomarker) 0 0
Development and Validation of Tissue Microarray Technology to Evaluate Molecular Alterations in Cancer. IRBMED# 2000-0108 0 0
Development of Breast Cancer Biomarkers Using DNA and Protein Microarray Technologies 0 0
Discovery of Novel Gene Elements Associated with Prostate Cancer Progression 0 0
EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge 0 0
EDRN Pre-Validation of Multiplex Biomarker in Urine 2 0
Evaluation of tissue biomarker of Urologic cancer, including prostate, bladder and kidneys using surplus human tissues 0 0
Identification of Novel Cancer Biomarkers in Serum and Urine Specimens 0 0
Molecular Profiling of Cancer: Identification and Characterization of Candidate Biomarkers and Regulatory Genes. IRBMED # 2001-0155 0 0
Pre-Validation of Metabolomic Biomarkers of Prostate Cancer 0 0
Pre-validation of TMPRSS2:ERG+PCA3 risk models for men on active surveillance 0 0
Tumor Profiling through High-throughput Sequencing 0 0
Prostate Biopsy Clinical Database/Tissue Bank IRBMED# 2004-0442 0 0

Closed Protocols

Protocol Name Biomarkers Datasets
EDRN-WHI Pre-Clinical Colon Ca Specimens 0 9


Publication Name PubMed ID Journal
Integrating biomedical knowledge to model pathways of prostate cancer progression. 17495538 Cell Cycle
Role of the TMPRSS2-ERG gene fusion in prostate cancer. 18283340 Neoplasia
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. 17356713 Neoplasia
Whole transcriptome amplification for gene expression profiling and development of molecular archives. 16611408 Neoplasia
Antibody-based detection of ERG rearrangement-positive prostate cancer. 20651988 Neoplasia
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. 20622896 Oncogene
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. 20526349 Nat. Med.
Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. 23348902 Mod. Pathol.
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. 23233736 Cancer Res.
New strategies in prostate cancer: translating genomics into the clinic. 23248095 Clin. Cancer Res.
Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. 23086769 Am. J. Clin. Pathol.
Epigenomic alterations in localized and advanced prostate cancer. 23555183 Neoplasia
The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells. 23118229 J. Biol. Chem.
Role of transcriptional corepressor CtBP1 in prostate cancer progression. 23097625 Neoplasia
Integrative molecular concept modeling of prostate cancer progression. 17173048 Nat. Genet.
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. 23358695 Neoplasia
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. 23159737 Mol. Cell
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. 23313952 Nat. Genet.
Integrative analysis of genomic aberrations associated with prostate cancer progression. 17804737 Cancer Res.
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. 18172298 Cancer Res.
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. 17671502 Nature
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. 17996646 Cancer Cell
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. 18006806 Cancer Res.
Humoral response profiling reveals pathways to prostate cancer progression. 18077443 Mol. Cell Proteomics
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. 18245462 Cancer Res.
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. 18483239 Cancer Res.
Molecular markers of prostate cancer. 17138135 Urol. Oncol.
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. 28344039 Cancer Cell
Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. 27926866 Cell Rep
Characterization of KRAS rearrangements in metastatic prostate cancer. 22140652 Cancer Discov
TACO produces robust multisample transcriptome assemblies from RNA-seq. 27869815 Nat. Methods
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. 17401460 Neoplasia
Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. 29245011 Cell
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. 28292441 Cancer Cell
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. 17059688 Neoplasia
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. 16951139 Cancer Res.
Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. 15173267 J. Natl. Cancer Inst.
Classification and selection of biomarkers in genomic data using LASSO. 16046820 J. Biomed. Biotechnol.
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. 16286247 Cancer Cell
Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. 27566105 Neoplasia
Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. 16678056 Urol. Oncol.
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. 16254181 Science
Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. 26280815 Cancer
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. 16585160 Cancer Res.
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. 17237811 Oncogene
Therapeutic targeting of SPINK1-positive prostate cancer. 21368222 Sci Transl Med
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. 22496589 Proc. Natl. Acad. Sci. U.S.A.
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. 22252602 Mol. Cancer Ther.
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. 21804560 Nat. Biotechnol.
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. 21724842 Genome Res.
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. 21575865 Cancer Cell
TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. 21676887 Cancer Res.
Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics. 27159573 Prostate
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. 22131877 Neoplasia
Personalized oncology through integrative high-throughput sequencing: a pilot study. 22133722 Sci Transl Med
Coordinated regulation of polycomb group complexes through microRNAs in cancer. 21840484 Cancer Cell
The emergence of lncRNAs in cancer biology. 22096659 Cancer Discov
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. 21813756 Sci Transl Med
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. 22101766 Nat. Med.
Systematic, evidence-based discovery of biomarkers at the NCI. 22868876 Clin. Exp. Metastasis
Autoantibody signatures in prostate cancer. 16177248 N. Engl. J. Med.
Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. 22952423 Neoplasia
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. 17334343 Mod. Pathol.
Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. 22849743 Arch. Pathol. Lab. Med.
The mutational landscape of lethal castration-resistant prostate cancer. 22722839 Nature
SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing. 22787087 Cancer Discov
Expressed pseudogenes in the transcriptional landscape of human cancers. 22726445 Cell
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. 22553170 J. Pathol.
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. 22610119 Nat. Genet.
Pathway-directed weighted testing procedures for the integrative analysis of gene expression and metabolomic data. 22497771 Genomics

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.


Department of Pathology , 1400 E. Medical Center Drive, 5316 CC
University of Michigan

To update addresses, please visit the Data Management and Coordinating Center.

🔜 Data-Sci Workshop
The EDRN Biomarker Data Science Workshop is coming this August, 2020. More details available soon.
Announcement 03/17/2020

The EDRN Registration page will be available soon to register for the 35th EDRN Steering Committee Meeting, now scheduled to take place from June 30-July 2, 2020, in Tempe, AZ.

This icon signifies that something is happening and we kindly ask you to please wait